Emblem Signs Key Supplier Agreement with Shoppers Drug Mart

Cannabis Investing News

Emblem Corp. (TSXV:EMC) (TSXV:EMC.WT) (“Emblem” or the “Company”), has announced today that it has entered into an agreement to become a medical cannabis supplier to Shoppers Drug Mart.

Emblem Corp. (TSXV:EMC) (TSXV:EMC.WT) (“Emblem” or the “Company”), has announced today that it has entered into an agreement to become a medical cannabis supplier to Shoppers Drug Mart.

Subject to Health Canada’s approval of Shoppers Drug Mart’s application to be a licensed producer, under the terms of the agreement the Company will supply Shoppers Drug Mart with Emblem branded medical cannabis products.  It is expected the products will be sold online, as Canadian regulations currently restrict the sale of medical cannabis in retail pharmacies.

Nick Dean, CEO of Emblem Corp., says the deal is an important milestone for Emblem. “From the very beginning we’ve been very focused on being a leader in the medical cannabis space, not only from the production side, but also when it comes to physician and patient education,” says Dean. “Today’s deal with Shoppers Drug Mart helps to solidify that and positions us well to be a world leader of cannabis for medical purposes.”

About Emblem
Emblem Corp., through its wholly-owned subsidiary Emblem Cannabis Corporation, is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the ACMPR (Access to Cannabis for Medical Purposes Regulations). Led by a team of cannabis experts and former health care and pharma executives, it has three distinct verticals – cannabis production, patient education centers, and pharmaceutical dosage form development. Emblem trades under the ticker symbol EMC on the TSX Venture Exchange.

For further information contact:

Ali Mahdavi
Vice President, Capital Markets and Investor Relations
Emblem Corp.
416.962.3300
alimahdavi@emblemcorp.com

Forward-looking statements

This news release may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation (together, “forward-looking statements”). All statements and information contained herein that is not clearly historical in nature may constitute a forward-looking statement. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements.

Forward-looking statements are not a guarantee of future performance and are subject to and involve a number of known and unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company’s actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks identified in the Company’s annual information form dated October 18, 2017 which has been filed with the Canadian Securities Administrators and is available on www.sedar.com. Any forward-looking statements contained herein are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent or otherwise.

Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by the Company from third parties and believes such information to be accurate but has not independently verified such information.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source: globenewswire.com

The Conversation (0)
×